Financial Metrics Exploration: Understanding Verona Pharma Plc ADR (VRNA) Through Ratios

Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The closing price of Verona Pharma Plc ADR (NASDAQ: VRNA) was $31.77 for the day, down -0.87% from the previous closing price of $32.05. In other words, the price has decreased by -$0.87 from its previous closing price. On the day, 1.33 million shares were traded. VRNA stock price reached its highest trading level at $32.52 during the session, while it also had its lowest trading level at $31.37.

Ratios:

Our analysis of VRNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.61 and its Current Ratio is at 8.61. In the meantime, Its Debt-to-Equity ratio is 1.30 whereas as Long-Term Debt/Eq ratio is at 1.29.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on October 03, 2024, initiated with a Overweight rating and assigned the stock a target price of $50.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 11 ’24 when ZACCARDELLI DAVID sold 600,000 shares for $3.76 per share. The transaction valued at 2,254,320 led to the insider holds 15,250,704 shares of the business.

Hahn Mark W sold 600,000 shares of VRNA for $2,254,080 on Sep 11 ’24. The Chief Financial Officer now owns 14,339,688 shares after completing the transaction at $3.76 per share. On Sep 11 ’24, another insider, MARK HAHN , who serves as the Officer of the company, bought 75,000 shares for $28.04 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRNA now has a Market Capitalization of 2580842240 and an Enterprise Value of 20546291712.

Stock Price History:

Over the past 52 weeks, VRNA has reached a high of $32.88, while it has fallen to a 52-week low of $11.39. The 50-Day Moving Average of the stock is 17.10%, while the 200-Day Moving Average is calculated to be 65.11%.

Shares Statistics:

VRNA traded an average of 1.19M shares per day over the past three months and 1032310 shares per day over the past ten days. A total of 80.44M shares are outstanding, with a floating share count of 62.79M. Insiders hold about 22.56% of the company’s shares, while institutions hold 62.19% stake in the company. Shares short for VRNA as of 1726185600 were 8849774 with a Short Ratio of 7.41, compared to 1723680000 on 10702654. Therefore, it implies a Short% of Shares Outstanding of 8849774 and a Short% of Float of 11.3800004.

Most Popular